Patients with mild to moderate COVID-19 are characterized by adequate type-I INF response while severe cases have low serum levels of type I INF, high viral load, and a dysregulated immune response with persistent hypercytokinemia and dysfunctional T cell response leading to acute distress respiratory syndrome (ARDS)5. The gene discussed is CBLIF; the disease is acute respiratory distress syndrome.